USFDA nod to Bristol Myers Squibb-2seventy bio Abecma for triple-class exposed relapsed or refractory Multiple Myeloma after 2 prior lines of therapy
Princeton: Bristol Myers Squibb and 2seventy bio, Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved Abecma (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody, […]